These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 23487374

  • 1. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
    Gatanaga H, Hayashida T, Tanuma J, Oka S.
    Clin Infect Dis; 2013 Jun; 56(12):1812-9. PubMed ID: 23487374
    [Abstract] [Full Text] [Related]

  • 2. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
    Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C, TECOVIR Study Group.
    Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
    [Abstract] [Full Text] [Related]

  • 3. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM.
    J Med Virol; 2007 Oct; 79(10):1464-71. PubMed ID: 17705185
    [Abstract] [Full Text] [Related]

  • 4. [Epidemiological and clinical features of occult hepatitis B in HIV infection without antiretroviral treatment].
    Zhang RF, Liu L, Zheng YF, Shen YZ, Chen J, Gu SM, Wang JR, Lu HZ.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):189-91. PubMed ID: 23967739
    [Abstract] [Full Text] [Related]

  • 5. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection.
    Heuft MM, Houba SM, van den Berk GE, Smissaert van de Haere T, van Dam AP, Dijksman LM, Regez RM, Brinkman K.
    AIDS; 2014 Apr 24; 28(7):999-1005. PubMed ID: 24685742
    [Abstract] [Full Text] [Related]

  • 6. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, Eholié SP, Maylin S, Delaugerre C, Zoulim F, Girard PM, Lacombe K, ANRS 12240 VarBVA study.
    Antivir Ther; 2015 Apr 24; 20(6):643-54. PubMed ID: 25852125
    [Abstract] [Full Text] [Related]

  • 7. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M.
    J Viral Hepat; 2012 Nov 24; 19(11):801-10. PubMed ID: 23043387
    [Abstract] [Full Text] [Related]

  • 8. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb 24; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 9. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, Guarrera JV, Emond JC, Brown RS.
    Transplantation; 2013 Apr 15; 95(7):960-5. PubMed ID: 23545507
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ.
    Hepatology; 2008 Oct 15; 48(4):1062-9. PubMed ID: 18697216
    [Abstract] [Full Text] [Related]

  • 11. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
    Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G, Gill MJ.
    J Clin Virol; 2014 Aug 15; 60(4):347-53. PubMed ID: 24881491
    [Abstract] [Full Text] [Related]

  • 12. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
    van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T.
    Hepatology; 2006 Aug 15; 44(2):318-25. PubMed ID: 16871563
    [Abstract] [Full Text] [Related]

  • 13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V.
    Antivir Ther; 2004 Jun 15; 9(3):353-63. PubMed ID: 15259898
    [Abstract] [Full Text] [Related]

  • 14. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L, Tebas P.
    J Infect Dis; 2002 Dec 15; 186(12):1844-7. PubMed ID: 12447773
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, 903 Study Team, 907 Study Team.
    J Infect Dis; 2004 Apr 01; 189(7):1185-92. PubMed ID: 15031786
    [Abstract] [Full Text] [Related]

  • 16. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
    Mendes-Correa MC, Pinho JR, Locarnini S, Yuen L, Sitnik R, Santana RA, Gomes-Gouvêa MS, Leite OM, Martins LG, Silva MH, Gianini RJ, Uip DE.
    J Med Virol; 2010 Sep 01; 82(9):1481-8. PubMed ID: 20648600
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun 01; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 18. Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
    N'Dri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni T, Chenal H, Seyler C, Gabillard D, Wakasugi N, Eholié S, Danel C.
    Antivir Ther; 2010 Jun 01; 15(7):1029-34. PubMed ID: 21041918
    [Abstract] [Full Text] [Related]

  • 19. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW.
    Gut; 2011 Feb 01; 60(2):247-54. PubMed ID: 21036792
    [Abstract] [Full Text] [Related]

  • 20. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Bárcena R, Del Campo S, Moraleda G, Casanovas T, Prieto M, Buti M, Moreno JM, Cuervas V, Fraga E, De la Mata M, Otero A, Delgado M, Loinaz C, Barrios C, Dieguez ML, Mas A, Sousa JM, Herrero JI, Muñoz R, Avilés JF, Gonzalez A, Rueda M.
    Transplant Proc; 2005 Nov 01; 37(9):3960-2. PubMed ID: 16386596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.